Coincidence of multiple endocrine neoplasia types 1 and 2: Mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4063-4067

  Frank Raue, Karin ^a,e   Rondot, Susanne ^a   Hoeppner, Wolfgang ^b   Goretzki, Peter ^c   Raue, Friedhelm ^a   Meng, Wieland ^d  

^a Endocrine Practice   (Germany)

^b Institute of Hormone Research   (Germany)

^c Lukas Krankenhaus   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e Endokrinologische Gemeinschaftspraxis   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PATHOGENESIS; PHENOTYPE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; TUMOR SUPPRESSOR GENE;

ADULT; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; RECURRENCE;

EID: 23044451691     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1759     Document Type: Article

References (25)

1. Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander HR, Chen CC, Chang R, Chandrasekharappa SC, Collins FS 2002 Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 17:N37-N43
2. Miedlich S, Krohn K, Paschke R 2003 Update on genetic and clinical aspects of primary hyperparathyroidism. Clin Endocrinol (Oxf) 59:539-554
3. Carling T 2001 Molecular pathology of parathyroid tumors. Trends Endocrinol Metab 12:53-58
4. Brandi ML, Gagel R, Angeli A, Bilezikian J, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri R, Libroia A, Lips C, Lombardi G, Manelli M, Pacini F, Ponder B, Raue F, Skogseid B, Tamburrano G, Thakker R, Thompson N, Tomasetti P, Tonelli F, Wells S, Marx S 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
5. Rizzoli R, Green J, Marx SJ 1985 Primary hyperparathyroidism in familial endocrine neoplasia type 1. Am J Med 78:467-474
6. Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B 1995 Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238:369-373
7. Rondot S, Clausmeyer S, Schulze E, Meng W, Spieker K, Höppner W, Goretzki P, Raue F Coincidence of multiple endocrine neoplasia type 1 and 2 caused by mutations in theMEN1gene and the RET protooncogene. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 311 (Abstract P1-678)
8. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R, Ploos van Amstel H, Lips C, Nishisho I, Takai S, Marsh D, Robinson B, Frank-Raue K, Raue F, Xue F, Noll W, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy G, Gharib H, Thibodeau S, Lacroix A, Frilling A, Ponder B, Mulligan L 1996 The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 276:1575-1579
9. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau P, Lenoir G, le Groupe D Etude des Tumeurs a Calcitonines 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutatons at codon 634 of the RET protooncogene. J Clin Endocrinol Metab 83:487-491
10. Rondot S, Vierhapper H, Baumgartner-Parzer S, Wagner L, Niederle B, Schulze E, Raue F 2004 Pitfalls in the genetic diagnosis of MEN2. Exp Clin Endocrinol Diabetes 112(Suppl 1):S1-S86 (P196)
11. Frank-Raue K, Heimbach C, Rondot S, Usadel K-H, Meng W, Varma C, Fuchs-Hammoser R, Höppner W, Schulze E, Raue F 2003 Hereditäres medulla ̈res Schilddrü sencarzinom-Genotyp-Phänotyp Charakterisierung. Dtsch Med Wochenschr 128:1998-2002
12. Gimm O, Ukkat J, Niederle B, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H 2004 Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 28:1312-1316
13. Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK 2002 Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 236:570-575
14. Jindrichova S, Vcelak J, Vlcek P, Neradilova M, Nemec J, Bendlova B 2004 Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol 183:257-265
15. Vierhapper H, Bieglmayer C, Heinze G, Baumgartner-Parzer S 2004 Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. Thyroid 14:580-583
16. Colombo-Benkmann M, Brämswig J, Höppner W, Gellner R, Hengst K, Böcker, W, Senninger N 2002 Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia. World J Surg 26:1286-1290
17. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven T, Roeher H, Wahl R, Lamesch P, Raue F, Conte-Devolx B, Dralle H 2003 Early malignant progression of hereditary medullary cancer. N Engl J Med 349:1517-1525
18. Machens A, Gimm O, Hinze R, Höppner W, Boehm B, Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104-1109
19. Pannett AAJ, Thakker RV 1999 Multiple endocrine neoplasia type 1. Endocr Relat Cancer 6:449-473
20. Hoff AO, Gagel RF 1997 Multiple endocrine neoplasia types 1 and 2: phenotype, genotype, diagnosis and therapeutic plan with special reference to children and adolescents. Curr Opin Endocrinol Diabetes 4:91-99
21. Ellard S, Hattersley AT, Brewer CM, Vaidya B 2005 Detection of an MEN1 gene mutation depends on clinical features and supports current criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf) 62:169-175
22. Jap T-S, Chiu C-Y, Won JD-S, Wu Y-C, Chen H-S 2005 Novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1. Clin Endocrinol (Oxf) 62:336-342
23. Carrasco CA, Gonzales AA, Carvajal CA, Campusano C, Oestreicher E, Arteaga E, Wohllk N, Fardella CE 2004 Novel intronic mutation of MEN1 gene causing familial isolated primary hyperparathyroidism. J Clin Endocrinol Metab 89:4124-4129
24. Cetani F, Pardi E, Giavannetti A, Cerrai P, Borsari S, Vignali E, Picone A, Cianferotti L, Miccoli P, Pinchera A, Marcocci C 2000 Six novel MEN1 gene mutations in sporadic parathyroid tumors. Hum Mut 16:445
25. Jensen RT 1998 Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 243:477-488